{Title}

China Healthcare Summit | 2018

BioCentury and BayHelix Present: The 5th China Healthcare Summit



November 13 - 14, 2018 | Shanghai

LOCATION

Jing An Shangri-La, Shanghai

REGISTRATION

Registration is now closed.


BioCentury and BayHelix Present: The 5th China Healthcare Summit

China's Globally Facing Future: How China’s healthcare pathfinders are leveraging the nation’s innovation, policy initiatives and access to capital markets in HK and domestic exchanges to build a globally facing industry. Five years ago, the first China Healthcare Summit asked how the nation would build the “Bridge to Innovation.” In 2018, we examine how China is now actually building the Bridge to Global Healthcare. A full two-day program highlighted by dialog among China-facing biotech innovators and their globally-facing Chinese counterparts.

The China Summit is a VIP-only event for busy biopharma and life sciences executives and investors to get a first-hand look at the innovation, business and policy transformations taking place in China. The conference is THE place to meet the right Chinese investors and partners in an intimate setting. The China Summit will include:

  • Two days of strategic sessions and keynotes tailored to help executives understand emerging opportunities and challenges in China.
  • The China Summit report created by Insights Partner, McKinsey & Company. This exclusive analysis documents market trends and identifies business imperatives for biopharma and life sciences companies doing business in China.
  • New for 2018: For the 1st time, the China Summit will feature a presenting company track to showcase biotechs from China, Asia and the West, hand-picked by BioCentury and BayHelix.
  • New for 2018: A 1x1 meeting system will allow attendees to arrange face-to-face discussions with investors and corporate delegates.
  • Three VIP receptions to network with senior-level executives and investors.
  • The annual BayHelix Awards ceremony and lunch to celebrate R&D and commercial achievements in China.
  • Multiple networking breaks throughout the event to meet peers across the China innovation ecosystem. 

The China Summit agenda has been developed by an Organizing Committee that includes China industry KOLs and BioCentury's editorial team. Simultaneous translation is provided in all strategic sessions.

Building Bridges To Innovation - The China Healthcare Summit Report by McKinsey & Company

Download the 2017 Report

Download the 2016 Report

Download the 2015 Report

BioCentury和百华协会联合承办:第五届China Healthcare Summit。本次峰会是为忙碌的生物制药和生命科学行业高管和投资者提供在中国发生的创新,商业和政策变化的一手信息而举办的贵宾活动。这次会议是与中国投资者和合作伙伴进行密切对话与沟通的地方。China Summit包括:

  • 为期两天的战略会议和主题演讲旨在帮助高管了解中国新兴的机遇和挑战
  • 由Insights合作伙伴麦肯锡公司创建的China Summit行业报告。这份独家分析材料记录了市场趋势和确定生物制药和生命科学公司在中国开展业务的商业需求
  • 2018年的新增:China Summit 将首次加入公司展示,包括来自中国,亚洲和西方的生物技术公司,由BioCentury和百华协会亲自挑选
  • 2018年的新增:一对一的会议系统将允许参会者安排和投资者及企业代表进行面对面的讨论
  • 三次贵宾招待会方便高层管理人员与投资者联络
  • 年度百华奖颁奖典礼和午宴,以表彰和庆祝在中国取得的研发和商业化成就
  • 会议期间有多场联谊空隙,方便与中国创新生态系统的同行互动

China Summit的会议议程由包括中国行业的关键意见领袖及BioCentury编辑团队在内的组织委员会定制。所有战略会议都提供同声传译。

搭建通向创新之桥-The China Healthcare Summit报告,麦肯锡咨询公司

下载 2017 年度报告

下载 2016 年度报告

下载 2015 年度报告


Return to Conferences List
SCHEDULE
8:50 AM to 9:00 AM
WELCOMING REMARKS
  • David Flores, President & CEO, BioCentury Inc.
  • Victor Shi, Ph.D., Chairman, BayHelix, and Managing Partner, Serica Partners
9:00 AM to 9:50 AM
BLUE RIBBON PANEL: CHALLENGES ON THE ROAD TO GLOBALIZATION

BayHelix convenes a special Blue Ribbon Panel to debate the mounting obstacles to globalization and their impact on China’s acceleration into the international healthcare ecosystem, its access to international talent and science, and its attractiveness as a destination for Western innovators and investors.

  • Kewen JIN, M.D., Managing Partner, Serica Partners (Session Chair & Moderator)
  • Tony Chen, Partner, Jones Day
  • Tao FU, President & Chief Operating Officer, Zai Lab
  • Nisa Leung, Managing Partner, Qiming Ventures
  • Bin LI, Ph.D., CEO, Ally Bridge LB Healthcare Fund
  • Lianshan ZHANG, Ph.D., SVP and President, Global R&D, Jiangsu Hengrui Medicine Co.
10:05 AM to 10:35 AM
BLUE RIBBON RAPPORTEUR SESSION: DOMESTIC BIOPHARMA

In a Fireside Chat, the leader of the innovative domestic biopharma industry association responds to points raised during the China Summit’s Blue Ribbon Panel: Challenges on the Road to Globalization.

  • Ruilin SONG, Executive President, PhIRDA (China Pharmaceutical Innovation and Research Development Association)
  • Victor Shi, Ph.D., Chairman, BayHelix & Managing Partner, Serica Partners (Moderator)
10:05 AM to 11:45 PM
PRESENTING COMPANIES TRACK (SESSION 1)
Ballroom 2

10:05am-10:25am Acepodia Inc. 10:25am-10:45am CBT Pharmaceuticals Inc. 10:45am-11:05am Insilico Medicine Inc.

11:05am-11:25am Hutchison China MediTech Ltd. (Chi-Med) (AIM/NASDAQ:HCM)

11:25am-11:45am Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN)

10:35 AM to 11:05 AM
BLUE RIBBON RAPPORTEUR SESSION: INTERNATIONAL BIOPHARMA

International biopharma leaders respond to points raised during the China Summit’s Blue Ribbon Panel: Challenges on the Road to Globalization.

  • David Flores, President & CEO, BioCentury Inc. (Session Chair & Moderator)
  • Steve Bates, CEO, BioIndustry Association (BIA)
  • Wei KANG, Managing Director, RDPAC (R&D-Based Pharmaceutical Association Committee)
  • Hyunsang MUK, President & CEO, Korea Drug Development Fund (KDDF)
11:05 AM to 11:50 PM
CHINA’S GLOBALIZATION CHALLENGE: INCUBATING BIOTECHS

Every nation recognizes the importance of incubating life science start-ups. But only a few succeed. The challenges are even higher for China as it races to do so in a rapidly changing landscape. What must it do to create a robust incubator ecosystem that serves both domestic and international priorities simultaneously?

  • Jimmy Wei, Ph.D., Managing Partner, Pivotal bioVenture Partners China (Session Chair & Moderator)
  • Laura Benjamin, Ph.D., Founder & CEO, Oncologie Ltd.
  • Da LIU, Managing Director, CR-CP Life Science Fund
  • Tyrone Mao, Senior Director, Scientific Innovation, JLABS@Shanghai
  • Karoly Nikolich, Ph.D., CEO & Chairman, Alkahest Inc.
  • Antoine Papiernik, Managing Partner, Sofinnova Partners
11:50 AM to 1:15 PM
PLENARY: PRESENTING COMPANIES: GLOBAL BIOTECH TRACK 1 (SESSION 2) AND BOXED LUNCH
Ballroom 1
  • Tao FU, President & Chief Operating Officer, Zai Lab Ltd. (emcee)

11:55am-12:15pm Zai Lab Ltd. (NASDAQ:ZLAB)

12:15pm-12:35pm Synaffix B.V.

12:35pm-12:55pm Arcus Biosciences Inc. (NYSE:RCUS)

12:55pm-1:15pm Xynomic Pharmaceuticals Inc.

1:20 PM to 2:10 PM
CHINA’S GLOBALIZATION CHALLENGE: DELIVERING RARE DISEASE SOLUTIONS AT HOME AND ABROAD?

By issuing its first national rare disease list, China has opened the door to a huge untapped market. But the pathway from clinic to reimbursement still must be built. As the market evolves, what must domestic and Western innovators do to deliver hope to patients in China? And how can Chinese biotechs make their presence felt in the global rare disease landscape?

  • James Xue, Ph.D., Chairman & CEO, Canbridge Life Sciences Ltd. (Session Chair & Moderator)
  • Kevin Huang, Founder & President, Chinese Organization for Rare Disorders (CORD)
  • David Oxley, SVP, Business Development & Licensing, Mesoblast Ltd.
  • Gonghua PAN, Co-Founder, General Manager & Chief Operating Officer, Kira Pharmaceuticals
  • Thaminda Ramanayake, Director, Business Development, BioMarin Pharmaceuticals
  • Bin WANG, Ph.D., Head of Business Development, Boehringer Ingelheim Biopharmaceuticals China
  • Richard Yang, Founder & CEO, Reflection Biotechnologies
1:20 PM to 3:00 PM
PRESENTING COMPANIES: U.K. BIOTECH TRACK 1 (SESSION 3)
Ballroom 2

Hosted by the BioIndustry Association (BIA), BioCentury and BayHelix

  • Steve Bates, CEO, BIA (emcee)
  • 1:20pm-1:40pm e-Therapeutics plc (LSE:ETX)

1:40pm-2:00pm Crescendo Biologics Ltd.

2:00pm-2:20pm F-star Biotechnology Ltd.

2:20pm-2:40pm Scancell Holdings plc (LSE:SCLP; FSE:SCP)

2:40pm-3:00pm Chain Biotechnology Ltd.

2:10 PM to 3:10 PM
CHINA’S GLOBALIZATION CHALLENGE: LEVERAGING ITS AI FUTURE

China’s commitment to population health, artificial intelligence and machine learning give it the wherewithal to make great strides in applying technology to domestic healthcare. Can it also create digital health powerhouses on a global scale?

  • Stanley Li, M.D., Founder, DXY (Session Chair)
  • Andrea de Souza, Senior Director, Informatics, Eli Lilly and Company (Moderator)
  • Chengming GU, M.D., VP, Medical Affairs, Greater China Region, Pfizer Inc.
  • Pek Lum, Ph.D., CEO & Founder, Auransa Inc.
  • Mao MAO, Ph.D., Founder & CEO, SeekIn Inc.
  • Tony Zhang, Founder & CEO, LinkDoc Technology (Beijing) Co.
  • Alex Zhavoronkov, Ph.D., Co-Founder & CEO, Insilico Medicine Inc.
3:00 PM to 6:00 PM
PRESENTING COMPANIES: CHINA BIOTECH TRACK (SESSION 4)
Ballroom 2

Hosted by BeiGene Ltd., BioCentury and BayHelix

  • Guillaume Vignon, Ph.D., SVP, Business Development, BeiGene Ltd. (emcee)
  • 3:00pm-3:20pm BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160)

3:20pm-3:40pm Laekna Therapeutics Shanghai Co. Ltd.

3:40pm-4:00pm Suzhou Ribo Life Science Co. Ltd.

4:00pm-4:20pm Yisheng Biopharma Co. Ltd.

4:20pm-4:40pm Abbisko Therapeutics Co. Ltd.

4:40pm-5:00pm Zhejiang Teruisi Pharmaceutical Inc.

5:00pm-5:20pm XW Laboratories Inc.

5:20pm-5:40pm PhageLux Inc.

5:40pm-6:00pm Elpiscience Biopharmaceuticals Co. Ltd.

3:40 PM to 4:30 PM
CHINA’S GLOBALIZATION CHALLENGE: BUILDING THE ACADEMIC-BIOTECH NEXUS

Global innovation has been built on the shoulders of academic institutions and biotech companies, which continue to convert new science into breakthrough treatments. The challenge is to create a clear path for assets and IP from the university into the hands of entrepreneurs. What must China’s universities, innovators and investors do to build an internationally recognized innovation engine?

  • Stella Xu, Ph.D., Managing Director, Quan Capital (Session Chair & Moderator)
  • Deborah Chen, Ph.D., Head of Business Development & Licensing, Drug Discovery and Development, A*STAR, Singapore
  • James Huang, Managing Partner, KPCB China, and Managing Partner, Panacea Venture
  • Liming SHAO, Ph.D., Professor and Director, Shanghai Center for iDrug Discovery & Development, School of Pharmacy, Fudan University
  • Litao ZHANG, Ph.D., VP, Leads Discovery & Optimization, Bristol-Myers Squibb Co.
  • Nick Zhang, Ph.D., Chairman & CEO, Qiagen Suzhou Translational Medicine Co. Ltd.
4:30 PM to 5:30 PM
WHITHER INNOVATION IN CHINA?

In the China Summit’s 3rd Annual Heads of Research Roundtable, R&D heads and “scientist-CEOs” from China and Abroad analyze how far China has come and what it now must accomplish to meet international expectations.

  • Steve Yang, Ph.D., EVP, Chief Business Officer, WuXi AppTec (Session Chair & Moderator)
  • Ruth Gimeno, Ph.D., VP, Diabetes Research & Clinical Investigation, Eli Lilly and Co.
  • Xiayang QIU, Ph.D., Founder, CEO & CSO, Regor Therapeutics Inc.
  • Weiguo SU, Ph.D., Executive Director & CSO, Chi-Med (Hutchison China MediTech Ltd.)
  • Lai WANG, Ph.D., SVP, Head of China Development, BeiGene Ltd.
  • Yinxiang WANG, Ph.D., Founder & Chairman, Beijing Jacobio Pharma Co. Ltd.
  • Doug Williams, Ph.D., President & CEO, Codiak BioSciences
6:00 PM to 10:00 PM
5TH ANNIVERSARY GALA DINNER AND AFTER PARTY

Celebrate the 5th anniversary of the BioCentury-BayHelix China Healthcare Summit with fellow delegates and Shanghai life sciences leaders at our Gala Dinner and After Party.

8:00 AM to 9:00 AM
PRESENTING COMPANIES: HONG KONG EXCHANGE SHOWCASE (SESSION 5) AND BREAKFAST NETWORKING
Ballroom 1

Hosted by: BioCentury and BayHelix

8:00am-8:20am GenScript Biotech Corp. (HKSE: 1548)

8:20am-8:40am Lee’s Pharmaceutical Holdings Ltd. (HKSE:950)

8:40am - 9:00am Hua Medicine Ltd. (HKSE:2552)

9:05 AM to 9:45 AM
KEYNOTE: THINKING BIG ABOUT CHINA’S HEALTHCARE ECOSYSTEM

China’s ambitious population health goals require brave initiatives, innovative partnerships and the skills of players from inside and outside the country. This opening keynote sets the stage for the day’s discussion about how globally facing companies can work across borders and across technologies to create a healthy China.

  • Leon Wang, EVP, International, AstraZeneca
9:45 AM to 10:45 AM
THE BRIDGE TO INNOVATION: LOOKING ACROSS TO 2025

Insights Partner McKinsey & Co. delivers the key findings from its 5th exclusive China Healthcare Summit Report for conference delegates, reflecting on what must be done to complete the Bridge to Innovation and where it could lead by 2025.

  • Fangning ZHANG, Partner, McKinsey & Co.
10:45 AM to 12:05 PM
PRESENTING COMPANIES: KOREA BIOTECH TRACK (SESSION 6)
Ballroom 2

Hosted by the Korea Drug Development Fund (KDDF), Kinhalo Ventures Korea, BioCentury and BayHelix

  • Tae-erk Kim, Chief Business Officer, KDDF (emcee)
  • 10:45am-11:05am Daewoong Pharmaceutical Co. Ltd. (KSE:069620)

11:05am-11:25am Bio-Pharm Solutions

11:25am-11:45am Bioneer Corp. (KOSDAQ: 064550)

11:45am-12:05pm Wellmarker Bio Co. Ltd.

11:00 AM to 12:10 PM
VIEW FROM THE TOP: BIOPHARMA GM PERSPECTIVES

In their 5th annual dialogue at the China Summit, general managers from the MNCs and China’s emerging class of multinational biotechs share their formulas for building a profitable product mix as the market access landscape undergoes its next round of reforms.

  • Aamir Malik, Senior Partner & Co-Leader, Global Pharmaceuticals and Medical Products Practice, McKinsey & Co. (Session Chair & Moderator)
  • Rogier Janssens, General Manager, China, Merck Biopharma China
  • Dirk Van Niekerk, General Manager, China, Boehringer Ingelheim
  • Thomas Willemsen, Chairman, GSK China Investment Co. Ltd.
  • Xiaobin WU, Ph.D., General Manager, China & President, BeiGene Ltd.
  • Shirley Zhao, M.D., General Manager & President, China and Hong Kong, Bristol-Myers Squibb Co.
12:10 PM to 1:40 PM
9TH ANNUAL BAYHELIX AWARDS LUNCH BANQUET

BayHelix again celebrates outstanding individuals and companies for their achievements and contributions to China’s healthcare ecosystem in five categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Person of the Year.

  • Victor Shi, Ph.D., Chairman, BayHelix, and Managing Partner, Serica Partners (emcee)
1:40 PM to 2:30 PM
READY TO CROSS THE BRIDGE?

As market pressures grow at home, Chinese pharmas are facing the imperative to globalize. Here’s how they plan to do it. Will they compete for deals with China’s internationally focused biotechs? And what does it mean for cross-border dealmakers from the West?

  • Kevin Li, Ph.D., Co-Founder & Managing Partner, LYZZ Capital (Session Chair & Moderator)
  • Darren Ji, Ph.D., CEO, Elpiscience Biopharmaceuticals Co. Ltd.
  • Peter Ji, Director, Business Development, Luoxin Pharmaceuticals
  • Ivor Royston, M.D., CEO, Viracta Therapeutics Inc.
  • Joan Shen, M.D., Head of R&D, I-Mab Biopharma
  • Donald Wyatt, VP, Business Development, 3SBio Inc.
1:50 PM to 4:50 PM
PRESENTING COMPANIES GLOBAL BIOTECH TRACK 2 (SESSION 7)
Ballroom 2

Hosted by Zai Lab Ltd., BioCentury and BayHelix

  • Tao FU, President & Chief Operating Officer, Zai Lab Ltd. (emcee)
  • 1:50pm-2:10pm Eureka Therapeutics Inc.

2:10pm-2:30pm Hookipa Biotech AG

2:30pm-2:50pm Boston Pharmaceuticals Inc.

2:50pm-3:10pm Codiak BioSciences Inc.

3:10pm-3:30pm Refuge Biotechnologies Inc.

3:30pm-3:50pm F1 Oncology Inc.

3:50pm-4:10pm Life Length S.L.

4:10pm-4:30pm Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT)

4:30pm-4:50pm MiNA Therapeutics Ltd.

2:30 PM to 3:20 PM
CHINA’S GLOBALIZATION CHALLENGE: NEW MODALITIES AND ADVANCED MANUFACTURING

In the race to lead in new therapeutic modalities like CAR T and other cell therapies, all roads run through manufacturing. But if global prowess in manufacturing is necessary, it is not sufficient. As China creates its beachhead in manufacturing, what more must it do to deliver these treatments to patients at home and abroad?

  • Chelsea Zhang, Partner, Ping An Ventures (Session Chair & Moderator)
  • Jie D’Elia, Ph.D., Executive Director, Business Development, Bristol-Myers Squibb Co.
  • James Li, M.D., CEO, JW Therapeutics Inc.
  • BG Rhee, CEO, SCM Life Sciences
  • Peter Wang, VP, Manufacturing, CMAB
  • Shuyuan YAO, Ph.D., VP & Head, Advanced Therapy Unit, China, WuXi AppTec
  • Li ZHU, Ph.D., Chief Strategy Officer, GenScript Biotech Corp. and Nanjing Legend Biotech
3:40 PM to 4:30 PM
CAPITAL MARKETS SHOWCASE: HOT MARKETS TODAY … WHAT ABOUT TOMORROW?

2018 is chasing records for global financing for public and private biotechs, with IPO news dominating in both Hong Kong and the U.S. But what will be the story in 2019? And how should China’s biotechs be building a strategy for accessing the capital markets over the long-term, not just when the market is hot?

  • Mengyu YU, Partner, Sidley Austin (Session Chair & Moderator)
  • Ziyi CHEN, China Healthcare Research Analyst, Goldman Sachs
  • Kenny Lam, Managing Director & Head of Healthcare Asia, Global Banking, HSBC
  • George Lin, EVP & CFO, Hua Medicine
  • Jonathan Wang, Ph.D., Co-founder & Senior Managing Director, OrbiMed Asia
  • Jinzi WU, Ph.D., Founder, Chairman & CEO, Ascletis Pharma Inc.
4:30 PM to 5:00 PM
INTERNATIONAL PERSPECTIVES: VOICES FROM ABROAD

In the Summit’s capstone rapporteur session, biotech leaders from the U.S., Europe and Asia reflect on what they have learned about China’s prospects for leadership at home and abroad in innovation and entrepreneurship.

  • Simone Fishburn, Ph.D., Executive Editor, BioCentury (Session Chair & Moderator)
  • Henk Joos, Director, Life Sciences, Healthcare & Agriculture, Agio Capital and Business Solutions
  • Brad Loncar, CEO, Loncar Investments
  • Kimberly Nearing, Managing Director & Head of Life Sciences, Cedrus Investments
  • Peter Pack, Ph.D., CEO, Crescendo Biologics Ltd.
  • Simranjit Singh, CEO, Asia, Middle East & Africa, Guardant Health Inc.
5:00 PM
CLOSING REMARKS
PRESENTERS
  • Abbisko
  • Acepodia
  • Arcus
  • ASLAN Pharmaceuticals
  • Beigene
  • Bio-Pharm Solutions
  • Bioneer
  • Boston Pharma
  • CBT Pharmaceuticals
  • Chain Biotech
  • Codiak
  • Crescendo
  • Daewoong
  • e-Therapeutics
  • Elpiscience Biopharmaceuticals Co Ltd
  • Eureka Therapeutics Inc
  • F-star Gmbh
  • F1 Oncology Inc.
  • GenScript
  • Hookipa Pharma Inc.
  • Hua Medicine
SPONSORS

The importance of the China Healthcare Summit is demonstrated by the commitment from its collaborators and supporting organizations. For information on sponsorship opportunities, please email Josh Berlin at BioCentury.

INSIGHTS PARTNER

  • {title}

U.K. BIOTECH TRACK HOST

  • {title}

KOREA BIOTECH TRACK HOST

  • {title}

CHINA BIOTECH TRACK HOST

  • {title}

GLOBAL BIOTECH TRACK HOST

  • {title}

5TH ANNIVERSARY GALA HOSTS

  • {title}
  • {title}

SPONSORS

  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}

SUPPORTING ORGANIZATIONS

  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}

SPEAKERS
Steve Bates

Steve Bates

Chief Executive Officer
BioCentury
Laura Benjamin, Ph.D.

Laura Benjamin, Ph.D.

President & CEO
Oncologie Inc.
Joshua Berlin

Joshua Berlin

Executive Director, New Ventures
BioCentury
Karen Bernstein, Ph.D.

Karen Bernstein, Ph.D.

Chairman
BioCentury
Deborah Chen

Deborah Chen

Head of Business Development and Licensing
Jie D’Elia, Ph.D.

Jie D’Elia, Ph.D.

Executive Director, Business Development Transactions
Andrea de Souza

Andrea de Souza

Senior Director
Simone Fishburn, Ph.D.

Simone Fishburn, Ph.D.

Editor in Chief
BioCentury
David Flores

David Flores

President & CEO
BioCentury
Tao Fu

Tao Fu

President & COO
Zai Lab
Ruth E. Gimeno

Ruth E. Gimeno

Diabetes Research and Clinical Investigation
Cheng-Ming Gu

Cheng-Ming Gu

Vice President, Chief Medical Officer
James Huang

James Huang

Managing Partner
KPCB China, and Founding Managing Partner, Panacea Venture
Rogier Janssens

Rogier Janssens

Managing Director and General Manager Biopharma
Darren Ji, Ph.D.

Darren Ji, Ph.D.

CEO
Peter Ji

Peter Ji

BD Director
Kewen JIN, M.D.

Kewen JIN, M.D.

Managing Partner
Serica Capital
Henk Joos, Ph.D.

Henk Joos, Ph.D.

General Manager
Agio Capital & Business Solutions
Kenny Lam

Kenny Lam

Managing Director
Franck Le Deu

Franck Le Deu

Senior Partner & Head of Greater China Healthcare Practice
McKinsey & Co.
Nisa Leung

Nisa Leung

Managing Partner
Qiming Venture Partners
Kevin Li, Ph.D.

Kevin Li, Ph.D.

Co-Founder & Managing Partner
LYZZ Capital